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Summary Taxol, a unique tubulin active agent, was found to demonstrate a marked schedule-dependent
synergistic interaction with cisplatin (DDP) in the killing of human ovarian carcinoma 2008 cells in vitro as
determined by median effect analysis. The interaction was highly synergistic when 19 h taxol exposure was
followed by I h concurrent exposure to taxol and DDP. The combination indices (CIs) on this schedule were
0.11 ± 0.1, 0.25 + 0.15 and 0.39 ± 0.14 at 20%, 50% and 80% cell kill respectively. However, the interaction
was antagonistic when 1 h exposure to DDP was followed by 20 h exposure to taxol, or when cells were
exposed to DDP and taxol for 1 h concurrently. When taxol preceded DDP, synergy was also observed with
the 11-fold DDP-resistant 2008/C13*5.25 subline, which yielded CI values of 0.21 ± 0.02, 0.30 ± 0.11 and
0.31 ± 0.17 at 20%, 50% and 80% cell kill respectively. At an IC50 concentration, taxol had no effect on
[3H]cis-dichloro(ethylenediamine) platinum uptake, on the permeability of the plasma membrane or on
glutathione or metallothionein levels in 2008 or 2008/C13*5.25 cells. Mitotic arrest in these cells was observed
only at taxol concentrations well above those required for synergy with DDP, suggesting that the mechanism
underlying the synergistic interaction was not a taxol-induced alteration in cell cycle kinetics. Of additional
interest was the fact that the 2008/Cl3*5.25 cells were hypersensitive to taxol, and that this was partially
explained by an alteration in the biochemical pharmacology of taxol. Although cellular taxol accumulation
reached steady state within 2 h in both cell lines, taxol efflux was slower and the taxol was more extensively
bound in 2008/C13*5.25 cells than in 2008 cells. In addition, the 2008/C13*5.25 cells had only 55% of the
parental levels ofP-tubulin content. However, in another pair of DDP-sensitive and -resistant ovarian cell lines
no taxol hypersensitivity and no change in P-tubulin content was observed, indicating that the DDP-resistant
and taxol-hypersensitive phenotypes do not segregate together. We conclude that taxol interacts synergistically
with DDP in a manner that is highly schedule dependent, and that the hypersensitivity of 2008/C13*5.25 cells
to taxol is unrelated to the mechanism of synergy. These in vitro observations suggest that drug schedule will
be an important determinant of the activity and toxicity of the DDP and taxol drug combination in clinical
studies.
DDP3 often produces good initial therapeutic responses in
ovarian carcinoma, but resistance to DDP develops fre-
quently, leading to chemotherapeutic failure. The
mechanisms reported to be capable of mediating DDP resis-
tance include increased cellular glutathione, increased metal-
lothionein, decreased drug uptake and Pt-DNA adduct for-
mation, and enhanced DNA repair (Andrews & Howell,
1990). Because of the clinical importance of DDP, there has
been wide interest in identifying agents that synergistically
modulate DDP activity at the cellular level. Only a few such
agents are known. Synergistic interactions have been reported
for DDP with cytarabine (Andrews et al., 1988; Keane et al.,
1990), 2'-deoxy-5-azacytidine (Frost et al., 1990), and
alkylating agents (Frost et al., 1990; Lidor et al., 1991;
Hayward et al., 1992). Anguidine (Hromas et al., 1984) and
forskolin (Mann et al., 1991) have been noted to enhance the
cellular uptake of DDP, whereas uptake is blocked by
aldehydes (Dornish & Pettersen, 1985; Dornish et al., 1986)
and ouabain (Andrews et al., 1988). Dipyridamole has been
identified as another agent capable of enhancing sensitivity to
DDP (Keane et al., 1990; Jekunen et al., 1992). Furthermore,
quercetin, tamoxifen and staurosporin have been found to
interact synergistically with DDP in Walker rat carcinoma
cells (Hofmann et al., 1989). The new phospholipid analogue
BM41440 inhibits protein kinase C and is reported to dem-
onstrate synergy with DDP (Hofmann et al., 1989).
Anti-microtubule agents are among the most important
anti-cancer drugs, and have significantly contributed to the
therapy of most curable neoplasms, such as Hodgkin's and
non-Hodgkin's lymphomas, germ cell tumours and childhood
leukaemias. While other anti-microtubule agents induce
microtubule disassembly, taxol promotes microtubule
assembly. Taxol has demonstrated a broad anti-tumour spec-
trum in preclinical studies (McQuire et al., 1989; Rowinsky et
al., 1990), and is active against DDP-unresponsive advanced
ovarian cancer, with a reported response rate of 24-33% in
phase II studies (Einzig et al., 1990).
Several studies of the combination of DDP and taxol for
the treatment of ovarian carcinoma are currently under way.
The goal of this study was to investigate the nature of the
interaction between DDP and taxol, and to determine whe-
ther the interaction demonstrated any schedule dependency.
We report here that there is a highly synergistic interaction
between these two drugs, but that the synergy is also highly
schedule dependent.
Materials and methods
Cell lines
Experiments were conducted using the human ovarian car-
cinoma line 2008 (DiSaia et al., 1972) and an 11-fold DDP-
resistant (2008/C13*5.25) subline generated by monthly
incubation in DDP (Andrews et al., 1985). The human
ovarian carcinoma A2780 and A2780CP cell lines were supp-
lied by R. Ozols (Fox Chase Cancer Institute, Philadelphia,
PA, USA). Cells were maintained in RPMI-1640 supple-
mented with 5% fetal bovine serum and 2 mM L-glutamine
without antibiotics. Cultures routinely tested negative for
mycoplasma by using Gen Probe kit (Gen Probe, San Diego,
CA, USA).
Clonogenic assays
Cells growing in log phase were harvested by trypsinisation,
washed, dispersed and plated onto 60 mm plastic tissue cul-
ture dishes (Corning Glass Works, New York, NY, USA) in
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triplicate at a density of 300 cells per dish. Cells were exposed
to taxol for 19 h and then, while the taxol exposure con-
tinued, to DDP for an additional hour. Alternatively, after
allowing cells to attach overnight, cultures were exposed to
either taxol and DDP concurrently, or first to DDP for 1 h
and then to taxol for 20 h. Cells were incubated in 5%
carbon dioxide at 37°C for 10 days, and then fixed with
methanol and stained using Giemsa dye in methanol.
Clusters of more than 40 cells were counted as one colony;
control dishes generally contained 100-130 colonies.
Median effect analysis
The nature of the interaction between DDP and taxol was
assessed by median effect analysis (Chou & Talalay, 1986;
Berenbaum, 1989). Dose-response curves were determined
for each agent alone, and with both agents in combination at
a fixed ratio equivalent to the ratio of their ICso values.
Computer analysis of the dose-response curves was used to
calculate the Cl at the level of 50% cell kill. Values of <I
indicate synergy, a value of 1 indicates additivity and values
> 1 indicate antagonism. Each point in the figures presented
represents the mean of three separate experiments using trip-
licate cultures (s.e.).
Electron microscopy
Monolayer cells were treated with 10 nM taxol for 24 h, then
fixed first in 2.5% (v/v) glutaraldehyde in 0.1 M sodium
phosphate buffer (pH 7.4, total osmolarity 0.52 osmol) and
then in 1% osmium tetroxide. Sections were cut parallel to
the culture surface on an LKB-V ultramicrotome (Pharmacia
LKB Biotechnology, Piscataway, NJ, USA). Thin sections
were stained with saturated uranyl acetate in 50% (v/v)
ethanol and then with bismuth subnitrate (Riva, 1974). Cells
were viewed with an H-600 transmission electron microscope
(Hitachi Instruments, Danbury, CT, USA). Sections of con-
trol and taxol-treated cells taken parallel to the plane of the
tissue culture dish were used to estimate the volume density
of microtubule bundles by point counting (Weibel, 1979;
Mathieu-Costello, 1987). Measurements were made at a final
magnification of 16,200 by placing a transparent overlay of a
400 point grid on random micrographs of cell sections taken
in the region of the nucleus. Four sections of four random
micrographs were analysed for each condition.
Intracellular pharmacology oftaxol
Taxol uptake was determined using [3H]taxol. One million
cells were seeded in 60 mm tissue culture dishes, and after 3
days, when cell cultures were in log phase growth, the influx
and efflux of taxol was determined. The medium was
aspirated, and fresh medium containing 0.1I,Ci ml-'
(27.8 nM) taxol was added for appropriate times to determine
influx. Cells were then washed three times with ice-cold PBS.
One millilitre of 1 nM sodium hydroxide was added and the
cells allowed to digest overnight. An aliquot was removed for
the determination of protein content by the method of Brad-
ford (1976) and 0.5 ml was used for liquid scintillation count-
ing.
In experiments designed to quantitate efflux, cells were first
loaded by incubating them in taxol (27.8 nM, 0.1,uCi ml-')
for 2 h, and then the medium was aspirated and fresh
medium containing no taxol was added. The efflux of taxol
was expressed as the percentage of taxol radioactivity
remaining in the cells as a function of time. The fraction of
[3H]taxol bound in 2008 and 2008/C13*5.25 cells was deter-
mined by ultrafiltration. The cells were first scraped from the
dish into PBS, and then sonicated at 4°C. One aliquot of
lysate was digested overnight in 1 ml of 1 M sodium hydrox-
ide and then used for protein determination and for radioac-
tivity measurement after neutralisation by 1 nM hydro-
choloric acid. The remaining lysate was ultrafiltered for
30 min at 4°C using Amicon CF25 cones (Amicon, Beverley,
MA, USA), and the radioactivity in the ultrafiltrate was
determined by liquid scintillation counting.
Effect oftaxol on cellular permeability
The effect of taxol on plasma membrane permeability was
tested by trypan blue exclusion. Log-phase cells were
trypsinised and resuspended at 500,000 cells ml-' in trypan
blue-containing fresh medium to which taxol had been
added. Cell staining after treatment with 10 nM, 100 nM
and 1 !LM taxol was followed by microscopy over 5 min.
Further experiments were done by adding trypan blue follow-
ing a 20 h incubation with 100 nM and 1 iLM taxol, and
subsequently examining the cells for uptake of trypan blue.
Effect oftaxol on cell cyclephase distribution
Cells in the log phase of growth were exposed to 0, 10,
100 nM and 2 tM taxol for 20 h, then harvested by trypsinisa-
tion, washed in PBS containing 2 mM magnesium chloride,
and fixed by adding 10 ml of 70% ethanol. Thereafter, cells
were kept at 4°C until flow cytometric analysis. Cells were
resuspended in 50tLM propidium iodide and 1,000 units ml-l
RNAse A in PBS, incubated at 37°C for 30 min, and
analysed on a Cytofluorograf (Ortho Diagnostics Systems,
Raritan, NJ. USA). Multicycle Cell Cycle Software (Phoenix
Flow Systems, San Diego, CA, USA) was used to calculate
the fraction of cells in each phase of the cell cycle. This
programme is based on the mathematical model described by
Dean and Jett (1974), using Gaussian distribution functions
for G, and G2/M phases, and a broadened second-degree
polynomial for S-phase. To assess the percentage of cells in
M-phase, a method based on difference in chromatin struc-
ture was used (Darzynkiewicz et al., 1977a,b). After fixation
and treatment with RNAse, cells were treated with acid and
stained with the metachromatic fluorochrome acridine orange
(Larsen et al., 1986). The extent of DNA denaturation per
cell was estimated from the ratio of red to green fluorescence
intensity. Metaphase and interphase cells were discriminated
on the basis of their red/green intensity ratios after partial
DNA denaturation.
Determination ofGSH content
Log-phase 2008 and 2008/Cl3*5.25 cells were treated with
taxol for 20 h before being harvested by trypsinisation,
washed with PBS, aliquoted in triplicate at 250,000 cells per
Eppendorf tube and pelleted for 2min at 2,000 r.p.m. The
medium was removed and 25 ll of MCB-Tris (2 mM MCB,
20 mM Tris-HCI, pH 8.0) was added, mixed and allowed to
react for 15 min in the dark. An equal volume (30pl) of
sodium methanesulphonate was then added to lyse the cells
and to precipitate cellular proteins. The GSH-containing
supernatant was assayed by the high-performance liquid
chromatography (HPLC) method of Fahey (1989) using 25 yl
injection volumes and a Waters C18 ;i-Bondapak cartridge
and precolumn. Data collection and processing were carried
on a Waters Maxima 820 system. Run time was 35 min with
a retention time of 10min.
Northern analysis ofmetallothionein mRNA
Total cellular RNA was harvested and electrophoresed in
formaldehyde gels, and blots containing 5jig per lane were
prepared on Nitroplus Membranes (Micron Separations,
Wesborough, MA, USA) (Davis et al., 1986; Sambrook et
al., 1989). Membranes were hybridised sequentially with 32p_
labelled cDNA probes for human metallothionein II (Karin
& Richards, 1982) and 0-actin (Gunning et al., 1983), the
latter used to control for lane loading.
Quantitation oftubulin subunits
Monoclonal antibodies directed against a- and P-tubulin were
used to quantitate tubulin subunits. Cells were harvested by
trypsinisation, fixed in 37% (v/v) formaldehyde in PBS
(pH 7.4) for 10 min at room temperature and permeabilisedINTERACTION BETWEEN CISPLATIN AND TAXOL IN VITRO
with 0.1% saponin in PBS for 5 min. Cells were incubated
with 100 nM monoclonal antibody in 3% bovine serum
albumin in PBS. After washing, the cells were stained with a
fluorescent goat anti-mouse IgG/IgM antibody for 45 min in
the dark, and then analysed on a CytoFluorograf (Ortho
Diagnostics Systems, Raritan, NJ, USA) with excitation and
emission settings of 488 and 530 nM respectively.
Results
Interaction between DDP and taxol
Figure 1 shows the clonogenic survival curves for DDP
alone, taxol alone, and the combination of DDP and taxol at
a fixed molar ratio of 7,500:1. The more negative slope of the
curve for the combination suggests an interaction between
the two drugs, but the nature of the interaction could not
readily be discerned since both agents were independently
cytotoxic (Berenbaum, 1989).
The nature of the interaction between taxol and DDP was
determined by using median effect analysis (Chou & Talalay,
1986), which provides a tool to examine the degree of
synergy, additivity or antagonism at various levels ofcell kill.
Median effect analysis permits calculation of the CI at
various levels of cell kill. CI values of 1 indicate additivity,
values of <1 synergy and values of > 1 antagonism; the
smaller the value of the CI below 1 the greater the degree of
synergy, and the greater the value above 1 the greater the
antagonism. Figure 2 shows the CI plot for some three
separate experiments as shown in Figure 1 in which DDP
and taxol were combined in a ratio of 7,500:1, which was the
ratio of their individual IC50 values. The curve demonstrates
synergy between DDP and taxol in the killing of 2008 cells
under conditions in which the cells were first treated with
taxol for 19 h and then with DDP and taxol concurrently for
1 h. At the 20% level of cell kill, the average CI was
0.11 ± 0.1 (s.e.m.; n = 3), indicating synergy. At the 50%
level of cell kill the mean CI was 0.25 ± 0.15 (s.e.m.; n = 3),
and it was 0.39 ± 0.14 (s.e.m.; n = 3) at the 80% level of cell
kill. The CI was significantly less than 1 (P<0.05) at all
three levels of cell kill, and these values indicate a very
strongly synergistic interaction.
Figure 3 shows the CI plot for the DDP-resistant 2008/
Cl3*5.25 cells also exposed to DDP and taxol in a ratio of
250:1 using the same schedule of pretreatment with taxol for
19 h followed by 1 h concurrent exposure to taxol and DDP.
Interestingly, these DDP-resistant cells were 5-fold hypersen-
sitive to taxol. The CI values for the 2008/Cl3*5.25 cells
were 0.21 0.02, 0.30 0.11 and 0.31 0.17 at 20%, 50%
10-
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Figure I Percentage survival as a function ofdrug concentration
for 2008 cells exposed to DDP for 1 h (circles), taxol for 19 h
(squares), and the combination of DDP and taxol, exposed first
to taxol for 19 h and then to taxol and DDP for 1 h at a fixed
molar ratio of 250:1 (triangles). Each point in all plots represents
the mean of three experiments using triplicate cultures (s.e.).
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Figure 2 CI as a function of extent of cell kill for 2008 cells
exposed first to taxol for 19 h and then to taxol and DDP for I h
at a molar ratio of 1:250. Each point in all plots represents the
mean of three separate experiments using triplicate cultures
(s.e.).
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Figure 3 CI as a function of extent ofcell kill for 2008/C13*5.25
cells exposed first to taxol for 19 h and then to DDP and taxol
for I h at a molar ratio of 7,500:1.
and 80% cell kill respectively. Thus, synergy was evident and
was statistically significant (P<0.05) over a range of 1 log of
cell kill in both cell lines, and hypersensitivity to taxol did
not affect the nature of the interaction between DDP and
taxol.
Figure 4 presents the CI curve for 2008 cells when the
same ratio ofdrugs was employed but on a schedule in which
the cells were first exposed to DDP for 1 h, following which
the medium was changed and the cells exposed to taxol for
20 h. This treatment schedule resulted in substantial
antagonism instead of the synergy over the first 2 logs of cell
kill.
Figure 5 shows the CI plot resulting from experiments in
which 2008 cells were exposed concurrently to DDP and
taxol for only I h. On this schedule, the IC50 concentrations
for DDP and taxol were 2.5pM and 50 nM, and because of
limits on the solubility of taxol the experiments were per-
formed at a DDP/taxol concentration ratio of 50:1. The CI
plot indicates antagonism between the two drugs on this
schedule.
Effect oftaxol on glutathione levels
The effect of a 20 h pretreatment with an IC50 concentration
of taxol on the GSH content of 2008 and 2008/C13*5.25 cells
is shown in Table I. The GSH levels were 2-fold higher in the
DDP-resistant cells (P = 0.00098, two-tailed unpaired t-test),
but taxol pretreatment did not alter the glutathione level in
either line.
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Effect oftaxol on cell cycle phase distribution
Sensitivity to DDP varies in different phases of the cell cycle,
being greatest in GI (Roberts & Fravel, 1980). One
mechanism mediating the schedule dependency of the syner-
gistic interaction between DDP and taxol may be taxol-
induced perturbation of the cell cycle phase distribution. In
subconfluent 2008 cell cultures, <6% of the cells were in
M-phase, approximately 40% were in S-phase, and the same
percentage were in GI (Table II). Exposure of 2008 cells for
20 h to an ICm concentration of taxol caused no change in
cell cycle phase distribution when assessed at time points out
to 72 h (data not shown). Likewise, the distribution did not
change when cells were exposed for 20 h to a concentration
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Figure 4 CI as a function of extent of cell kill for 2008 cells
exposed first to DDP and then taxol for 20 h at a molar ratio of
1:250.
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molar ratio of 1:50.
Table I Effect of taxol on GSH coi
Cell type Taxol
2008
+
2008/Cl 3*5.25
+
8llmol per 2.5 x 105 cells.
10 times the IC50. In contrast, exposure of the cells to a taxol
concentration of 2 JiM (200 times the ICjo) for 20 h blocked
approximately 50% of the cells in M-phase. Twenty-four
hours after the end of exposure to 2 gM taxol (i.e. at hour 44)
some additional G2 arrest was apparent as 86.5% of the cells
were in G2/M-phase, but only 25% were in M-phase. Thus at
concentrations at which synergy with DDP was apparent,
taxol did not have any measurable effect on the cell cycle
phase distribution.
Effect oftaxol on microtuluble polymerisation
Despite the fact that very high concentrations of taxol were
required to produce M-phase arrest, Figure 6 shows that a
24 h exposure to even 10 nM taxol (equivalent to the IC50)
was sufficient to cause characteristic formation of micro-
tubule bundles in 2008 cells. The volume density of bundles
was determined by stereological analysis of electron micro-
graphs. Cells attached to plastic dishes were cut parallel to
the plane of the dish in a region including the nucleus. The
volume density of microtubule bundles was 5 ± 3% and
11 ± 5% in the control and taxol-treated 2008 cells respec-
tively (P<0.04, two-sided t-test). Thus, at concentrations at
which taxol demonstrated synergy with DDP, it was capable
of altering microtubular morphology even though not
capable of causing cell cycle arrest.
Taxol effects on metallothionein levels measured by Northern
analysis
A 20 h treatment with an IC50 taxol concentration had no
effect on metallothionein IIA message levels in 2008 or 2008/
C13*5.25 (data not shown). A 50-fold DDP-resistant subline,
2008/Cl3*50, which constitutively overexpresses metal-
lothionein IIA, was included as a positive control. A 20 h
exposure to an IC50 concentration of taxol did not increase
metallothionein IIA expression in this line either.
Hypersensitivity ofDDP-resistant cells to taxol
Separate from the fact that DDP and taxol exhibit schedule-
dependent synergy, the observation that the DDP-resistant
2008/C13*5.25 cells were actually 5-fold hypersensitive to
taxol is of substantial interest with regard to the use of these
drugs in combination. As a first step towards identifying the
mechanism underlying this collateral hypersensitivity we
compared the two cell lines with respect to the biochemical
,,,I, pharmacology of taxol. Figure 7a shows the time course of
0.8 1 taxol accumulation in 2008 and 2008/C13*5.25 cells; consis-
tent with our previous results (Christen et al., 1993), there
was no difference in either the initial influx of [3H]taxol or
for 2008 cells steady-state content. Figure 5b shows the time course of
at a DDP/taxol efflux after the cells had been loaded by incubation in taxol-
containing medium for 120 min, then washed and allowed to
efflux into taxol-free medium. At 30 min after the start of
efflux, the 2008/C13*5.25 cells had lost 10% of their initial
ntent content of drug, whereas the 2008 cells had lost 53%. These
results suggested that there was either a decreased efflux rate
GSH contenta constant or increased intracellular binding of taxol in the
32.6 6.0 2008/Cl3*5.25 cells. Ultrafiltration experiments were done to
34.5 4.7 determine the fraction of taxol-bound intracellularly at
63.7 23.2 steady state. Table III shows that approximately 16%
53.8 18.5 drug was ultrafilterable in the 2008 than the 2008/C13*5.25
cells, both at steady state and at 90 min after the start of
Table II Effects of taxol on the cell cycle phase distribution of 2008 cells
Control Taxol 10 nM Taxol 100 nM Taxol 2,000nM
20h 44h 20h 20h 44h 20h 44h
GI 41.2± 3.0a 41.0± 2.4 42.8 ± 1.2 42.3 ± 1.3 40.6± 1.6 11.3 ± 2.4 4.5 ± 1.3
S 43.9 ± 5.4 40.1 ± 2.4 44.1 ± 1.6 43.7 ± 2.4 41.6 ± 1.2 17.8 ± 2.6 9.0 ± 1.6
G2/M 14.9 ± 3.6 18.9 ± 1.0 13.1 ± 2.8 14.0 ± 3.3 17.8 ± 0.7 70.9 ± 5.0 86.5 ± 1.2
M 1.6±0.3 5.9± 1.5 1.4±0.4 1.5±0.3 4.8± 1.3 54.9±4.5 23.7± 1.8
aEach point shows the mean of three experiments (± s.d.).
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Figure 6 Transmission electron micrographs of 2008 cells
exposed for 24h to 10nM taxol. Arrows indicate characteristic
hyperpolymerised tubulin bundles. a, 2008 cell at 16,000
magnification. b, 2008 cell at 150,000 magnification.
drug efflux. Thus, increased intracellular binding of taxol
contributed to the difference in the extent of taxol efflux
observed between the two cell lines, but other mechanisms
are likely to be involved as well since the magnitude of the
difference in intracellular binding is substantially less than the
difference in the extent of efflux at 90 min. It should be noted
that neither of the cell types expresses the mdrl gene detec-
table by either Northern blotting, PCR amplification or
immunohistochemical staining (data not shown). However,
2008/C13*5.25 cells do demonstrate an abnormality of
tubulin content. They contain only 55 + 8% (s.d.) of the
parental content of P-tubulin (P<0.0002, two-sided paired
t-test), while a-tubulin content is unchanged (Christen et al.,
1993).
To determine whether hypersensitivity to taxol was a con-
sistent feature of the DDP-resistant phenotype in ovarian
carcinoma cell lines, we examined the taxol sensitivity of
another pair of DDP-sensitive and -resistant human ovarian
carcinoma cells, A2780 and A2780CP cells. While the A2780CP
cells are 6-fold resistant to DDP, they showed no difference
in sensitivity to taxol using a 20 h exposure (Figure 8). In
addition, they showed no abnormality of tubulin content.
The A2780cP cells contained 92 ± 17% and 95 ± 13%, respec-
tively, of the a- and ,B-tubulin present in the parental 2780
Figure 7 a, Uptake and b, Efflux of [3H]taxol into and from
2008 cells (open circles) and 2008/Cl3*5.25 cells (closed circles).
Each point represents the mean of three experiments performed
with triplicate cultures. Vertical bars represent s.d.
Table III Percentage [3H]taxol ultrafiltrable at steady state and
during efflux
Cell line
Exposure conditions 2008 2008/C13*5.25
Two hours incubation with taxol 69.1 ± 8.9a 53.4 4.5
Four hours incubation with taxol 69.6 + 6.0 53.3 ± 5.5
Two hours incubation with taxol 68.4 ± 7.1 58.0 ± 2.7
followed by 90 min efflux
into drug-free medium
aEach value is the mean of two experiments performed with
quadruplicate cultures.
cells. Thus, taxol hypersensitivity does not co-segregate with
the DDP-resistant phenotype in ovarian carcinoma cell
lines.
Discussion
These studies demonstrated a highly synergistic cytotoxic
interaction between DDP and taxol, but also demonstrated
that this interaction was very schedule dependent. Synergy
was noted only when taxol exposure preceded a 1 h exposure
to DDP. Both a 1 h concurrent exposure to both drugs and a
I h exposure to DDP followed by a 20 h exposure to taxol
produced an antagonistic interaction. These results have
important clinical implications for the use of these two drugs
in combination for the treatment of ovarian carcinoma. First,
they suggest that the optimal anti-tumour effect will be
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triplicate cultures.
obtained through a schedule which permits
establishment of taxol effect before the adr
DDP. Second, since synergy was observed wi
sensitive and DDP-resistant cells, it may be p
advantage of the synergistic interaction in bo
nosed patients with DDP-sensitive tumour
patients failing primary chemotherapy with
analogues. It should be emphasised that taxol
interact synergistically with respect to toxic
tissues as well, and this may necessitate clinica
than fully synergistic schedule.
Administration of taxol before DDP was
result in greater anti-tumour activity thar
schedule when tested against L1210 murine leu
vitro by Citardi et al. (1990). In these cells, a
to taxol followed by a 30 min exposure to
greater cell kill than either concurrent exposure
or a sequence consisting of a 30 min expo
followed by a 24 h exposure to taxol. The relat
values in the presence of taxol were 28%, 100'
those for DDP alone on the three schedules. F
(1991) showed in a phase I trial that myelosi
less profound when taxol was given prior to
with the reverse schedule. However, this differe
was associated with a higher clearance of tax(
given before rather than after DDP, and the
drug on the sensitivity to the other at the cellu
not be assessed. Nevertheless, based on ti
sequence of taxol administered prior to DDP M
further clinical development (Rowinsky &
1991).
DDP sensitivity is related to the extent of dri
in fact in studies reported elsewhere (Christen X
have shown that a 20 h exposure to taxol
a causing a concentration-dependent increase in the uptake of
[3H]DEP, a tritiated analogue of DDP. This effect was pro-
duced in the absence of any plasma membrane damage as
measured by the ability of the cells to exclude trypan blue,
indicating that the increase in [3H]DEP uptake was not due
to a non-specific increase membrane permeability. However,
the concentrations of taxol required to produce increased -i 'uptake (100 nM to 1jiM) were > 10-fold above the IC50.
Taxol was able to produce synergistic killing of cells with
DDP at concentrations that were far below those required to
increase [3H]DEP uptake.
Although cellular content of GSH has been reported to be
one determinant of DDP sensitivity, taxol caused no change
in the GSH level of either 2008 or 2008/C13*5.25 cells.
40 50 Likewise, concentrations of taxol capable of interacting
synergistically caused no increase in metallothionein
b messenger RNA, and by inference total metallothionein con-
tent.
Taxol characteristically causes cells to arrest in M-phase.
One might hypothesise that taxol was interacting synergis-
tically with DDP by virtue of its ability to cause cells to
accumulate in a particularly DDP-sensitive portion of the cell
cycle. However, cells have been reported to be most sensitive
to DDP in the GI phase of the cell cycle (Drewinko et al.,
1980), and taxol caused no detectable perturbation of the cell
cycle phase distribution of 2008 cells at the concentrations
required for synergy.
Although we have been unable to identify the mechanism
underlying the schedule-dependent synergistic interaction
between DDP and taxol, it is noteworthy that both drugs
150 have been reported to interact with tubulin. Taxol charac-
teristically causes a stabilisation of tubulin, resulting in
hyperpolymerisation (Schiff et al., 1979), and in fact does so iscentratlon for in 2008 cells even at concentrations as low as 10 nM. DDP
llol.lEahowint
as has been reported by Rixe et al. (1993) to cause polymerisa-
onducted with tion of tubulin, but by Peyrot et al. (1986) to cause depoly-
merisation. Further evidence for an effect of DDP on tubulin
comes from the fact that 2008/C13*5.25 cells have both a
decrease in ,B-tubulin and altered tubulin structure visible on
confocal microscopy (Christen et al., 1993). We speculate
that the synergistic interaction may be occurring at the pro-
some time for tein rather than at the DNA level.
ninistration of It is equally of interest that 1 h DDP exposure was able to
ith both DDP- decrease the sensitivity of cells to a subsequent exposure to
oossible to take taxol, resulting in strong antagonism between the two drugs
ith newly diag- with respect to cytotoxicity even at low concentrations of
*s as well as taxol. Given the fact that DDP-induced G2 arrest does not
DDP or its become manifest for >24 h in 2008 cells, and that it requires
and DDP may quite high concentrations of taxol to produce the characteris-
-ity to normal tic M-phase arrest, it is unlikely that the antagonism was on
il use of a less the basis of cytokinetic perturbations, but one can speculate
that DDP might be altering the tubulin binding site for taxol
also shown to or that taxol-induced alterations in tubulin could be interfer-
n the reverse ing with DDP DNA formation or persistence. Taxol concen-
ikaemia cells in trations as low as 1 nM have been shown to promote tubulin
24 h exposure polymerisation and shift the equilibrium in favour of mic-
)DP produced rotubule assembly (Roytta et al., 1987).
to both drugs Unexpectedly, the 2008/C13*5.25 cells were found to be
osure to DDP 5-fold hypersensitive to taxol. Biochemical pharmacology
tive DDP LD90 studies showed that this hypersensitivity was associated with
% and 83% of a markedly reduced efflux of taxol following drug loading, a
towinsky et al. small increase in intracellular binding and the above-
ippression was mentioned changes in 3-tubulin content and structure
)DP compared (Christen et al., 1993). However, study of the A2780 and
mnce in toxicity A2780CP cell lines demonstrated that this taxol-hypersensitive
ol when it was phenotype did not segregate with that of DDP resistance,
effect of one and thus we conclude that the taxol hypersensitivity of the
ilar level could 2008/C13*5.25 cells was due to an abnormality of tubulin
hese data the unique to these particular cells. DDP is mutagenic (Chibber
vas selected for & Ord, 1989), and it is conceivable that during the process of
Donehower, selection for resistance to DDP 2008/Cl3*5.25 cells acquired
alterations in one or more tubulin or tubulin-associated pro-
ug uptake, and tein genes. In several yeast models it has been shown that the
et al., 1993) we accumulation ofa-tubulin in excess over P-tubulin is uniquely
is capable of toxic because it interferes with normal microtubule assembly
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(Weinstein & Solomon, 1990). Overexpression of ,B-tubulin
resulted in loss of normal microtubular structures and
viability, but an excess of a-tubulin over P-tubulin was not
toxic(Weinstein & Solomon, 1990). Given that theratio ofa- to
,B-tubulin was no different in the A2780CP than in the A2780
cells, whereas the amount of P-tubulin in 2008/C13*5.25 cells
was decreased relative to that of a-tubulin (Christen et al.,
1993), it is conceivable that the, response to taxol was also
altered.
Peak plasma concentrations of taxol range from a mean of
0.95 LM for 275mgm-2 given as a constant rate infusion
over 24h to >8 tM when given at a dose of 275 mgm-2
over 6 h (Wiernik et al., 1987a,b). Thus, the attainable
plasma concentrations of taxol are well above the range
necessary to demonstrate synergistic killing when combined
with DDP. The schedule-dependent synergy between these
two drugs will further complicate the clinical assessment of
combination taxol/DDP therapy for patients with ovarian
cancer
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